新冠病毒疫苗：实施情况、局限性与机遇
COVID-19 vaccines: implementation, limitations and opportunities.
作者信息
Richman Douglas D
机构信息
University of California San Diego, Distinguished Professor of Pathology and Medicine (Active Emeritus); Director, The HIV Institute; Co- Director, San Diego Center for AIDS Research; Florence Seeley Riford Emeritus Chair in AIDS Research, CA, USA.
出版信息
Glob Health Med. 2021 Feb 28;3(1):1-5. doi: 10.35772/ghm.2021.01010.
Abstract
The speed of development and the magnitude of efficacy of recently developed vaccines directed against SARS-CoV-2 has been truly remarkable. This editorial will not summarize the highly publicized and reviewed information about the design and clinical trial results of these vaccines. Rather, I will speculate about several issues regarding ) considerations of the rollout and implementation of the multiple vaccines, ) the use of the vaccines in ways different from those used in the registrational phase 3 studies, ) the future both of SARS-CoV-2 in the human population and of "normal" human life returning after widespread vaccination, and ) the implications of the success of these SARS-CoV-2 vaccines for vaccine development against other pathogens.
摘要
最近研发的针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的疫苗，其研发速度和功效程度着实令人瞩目。本社论不会总结这些疫苗的设计和临床试验结果等已被广泛宣传和审查的信息。相反，我将推测几个问题，包括：一、多种疫苗推广和实施的考量；二、疫苗使用方式与注册3期研究中的使用方式的不同之处；三、SARS-CoV-2在人群中的未来以及广泛接种疫苗后“正常”人类生活的回归；四、这些SARS-CoV-2疫苗的成功对针对其他病原体的疫苗研发的影响。
相似文献
1
COVID-19 vaccines: implementation, limitations and opportunities.新冠病毒疫苗：实施情况、局限性与机遇
Glob Health Med. 2021 Feb 28;3(1):1-5. doi: 10.35772/ghm.2021.01010.
2
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗（灭活，Vero 细胞）有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
3
A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.一项在已接种 SARS-CoV-2 疫苗的≥75 岁成年人中评估不同 COVID-19 疫苗免疫原性和反应原性的多国、2 期、随机、自适应方案：在 VACCELERATE 网络内开展的一项试验。
Trials. 2022 Oct 8;23(1):865. doi: 10.1186/s13063-022-06791-y.
4
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.评价由科兴中维生产的新型冠状病毒（灭活）疫苗对医护人员的有效性和安全性的双盲、随机、安慰剂对照 III 期临床试验 - PROFISCOV：一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Oct 15;21(1):853. doi: 10.1186/s13063-020-04775-4.
5
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.智利科兴和国药疫苗接种后动态 IgG 血清阳性率：哨点监测研究。
Lancet Infect Dis. 2022 Jan;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5. Epub 2021 Sep 9.
6
COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.新冠疫情和疫苗更新：挑战与解决方案。
Front Cell Infect Microbiol. 2021 Sep 10;11:690621. doi: 10.3389/fcimb.2021.690621. eCollection 2021.
7
Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi.两种灭活严重急性呼吸综合征冠状病毒2疫苗加强接种对成人有症状的冠状病毒病感染的疗效和安全性：在阿布扎比进行的一项双盲、随机、安慰剂对照3期试验的结果
Vaccines (Basel). 2023 Jan 30;11(2):299. doi: 10.3390/vaccines11020299.
8
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.新冠疫苗的快速研发和早期成功为加速癌症治疗机制带来了希望。
Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1.
9
The way of SARS-CoV-2 vaccine development: success and challenges.SARS-CoV-2 疫苗的研发之路：成功与挑战。
Signal Transduct Target Ther. 2021 Nov 9;6(1):387. doi: 10.1038/s41392-021-00796-w.
10
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.一种基于重组串联重复二聚体 RBD 的蛋白亚单位疫苗（ZF2001）在成年人中的安全性和免疫原性：两项随机、双盲、安慰剂对照、1 期和 2 期临床试验。
Lancet Infect Dis. 2021 Aug;21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. Epub 2021 Mar 24.
引用本文的文献
1
Integration of metabolomics and chemometrics with in-silico and in-vitro approaches to unravel SARS-Cov-2 inhibitors from South African plants.整合代谢组学和化学计量学，结合计算机模拟和体外实验方法，从南非植物中筛选出新型冠状病毒（SARS-CoV-2）抑制剂。
PLoS One. 2025 Mar 26;20(3):e0320415. doi: 10.1371/journal.pone.0320415. eCollection 2025.
2
Identification of South African Plant-Based Bioactive Compounds as Potential Inhibitors against the SARS-CoV-2 Receptor.鉴定南非植物源生物活性化合物作为针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）受体的潜在抑制剂。
Pharmaceuticals (Basel). 2024 Jun 22;17(7):821. doi: 10.3390/ph17070821.
3
Wide-range and selective detection of SARS-CoV-2 DNA via surface modification of electrolyte-gated IGZO thin-film transistors.通过电解质门控铟镓锌氧化物薄膜晶体管的表面修饰实现对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）DNA的宽范围和选择性检测。
iScience. 2024 Feb 1;27(3):109061. doi: 10.1016/j.isci.2024.109061. eCollection 2024 Mar 15.
4
Boosting COVID-19 vaccine inoculation and booster shots: a systematic review and meta-analysis of factors that influence Coronavirus vaccine uptake in practice.促进 COVID-19 疫苗接种和加强针：影响实际中冠状病毒疫苗接种率的因素的系统评价和荟萃分析。
Afr Health Sci. 2023 Jun;23(2):3-22. doi: 10.4314/ahs.v23i2.3.
5
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.二价 BNT162b2 疫苗接种的医护人员（有或无风险因素）或感染奥密克戎后，对奥密克戎亚谱系（BA.2/BA.5/BQ.1.1/XBB/XBB.1.5）的中和作用。
Sci Rep. 2023 Oct 13;13(1):17404. doi: 10.1038/s41598-023-44484-x.
6
Molecular Characterization and Selection of Indigenous SARS-CoV-2 Delta Variant for the Development of the First Inactivated SARS-CoV-2 Vaccine of Pakistan.用于开发巴基斯坦首款新冠病毒灭活疫苗的本土新冠病毒德尔塔变异株的分子特征分析与筛选
Vaccines (Basel). 2023 Mar 7;11(3):607. doi: 10.3390/vaccines11030607.
7
Identification of SARS-CoV-2 M inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2.鉴定出含有 SARS-CoV-2 M 抑制剂的 P1' 4-氟苯并噻唑部分，对 SARS-CoV-2 具有高度活性。
Nat Commun. 2023 Feb 25;14(1):1076. doi: 10.1038/s41467-023-36729-0.
8
The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的德尔塔和奥密克戎变体：我们目前所了解的情况。
Vaccines (Basel). 2022 Nov 14;10(11):1926. doi: 10.3390/vaccines10111926.
9
Neutralization activity of sera/IgG preparations from fully BNT162b2 vaccinated individuals against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Kappa variants.完全接种 BNT162b2 疫苗的个体的血清/IgG 制剂对 SARS-CoV-2 Alpha、Beta、Gamma、Delta 和 Kappa 变异株的中和活性。
Sci Rep. 2022 Aug 8;12(1):13524. doi: 10.1038/s41598-022-17071-9.
10
Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial.肌肉注射、单剂量 V590（rVSV-SARS-CoV-2 疫苗）在健康成年人中的安全性和免疫原性：一项 1 期随机、双盲、安慰剂对照、剂量范围试验的结果。
EBioMedicine. 2022 Aug;82:104138. doi: 10.1016/j.ebiom.2022.104138. Epub 2022 Jul 6.
本文引用的文献
1
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.SARS-CoV-2 从高中和性的 COVID-19 恢复期血浆中逃逸。
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36). doi: 10.1073/pnas.2103154118.
2
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.南非新冠病毒 501Y.V2 变异株可逃避南非捐赠者血浆的中和作用。
Nat Med. 2021 Apr;27(4):622-625. doi: 10.1038/s41591-021-01285-x. Epub 2021 Mar 2.
3
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.一剂接种和加强针接种时间对 ChAdOx1 nCoV-19（阿斯利康）疫苗免疫原性和有效性的影响：四项随机试验的 pooled 分析。
Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19.
4
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.基于 rAd26 和 rAd5 载体的异源初免-加强型 COVID-19 疫苗的安全性和有效性：俄罗斯一项随机对照 3 期临床试验的中期分析。
Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2.
5
Vaccinology in the post-COVID-19 era.后 COVID-19 时代的疫苗学。
Proc Natl Acad Sci U S A. 2021 Jan 19;118(3). doi: 10.1073/pnas.2020368118.
6
Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.黄热病疫苗小剂量的免疫原性和安全性：一项随机、双盲、非劣效性试验。
Lancet. 2021 Jan 9;397(10269):119-127. doi: 10.1016/S0140-6736(20)32520-4.
7
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
8
Viral targets for vaccines against COVID-19.针对 COVID-19 的疫苗的病毒靶点。
Nat Rev Immunol. 2021 Feb;21(2):73-82. doi: 10.1038/s41577-020-00480-0. Epub 2020 Dec 18.
9
Shots of hope.希望之针。
Science. 2020 Dec 18;370(6523):1392-1394. doi: 10.1126/science.370.6523.1392.
10
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
Zotero 插件